These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 27226502)

  • 1. Major Changes in Systemic Therapy for Advanced Melanoma.
    Thompson JA
    J Natl Compr Canc Netw; 2016 May; 14(5 Suppl):638-40. PubMed ID: 27226502
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Potential clinical and immunotherapeutic utility of talimogene laherparepvec for patients with melanoma after disease progression on immune checkpoint inhibitors and BRAF inhibitors.
    Chesney J; Imbert-Fernandez Y; Telang S; Baum M; Ranjan S; Fraig M; Batty N
    Melanoma Res; 2018 Jun; 28(3):250-255. PubMed ID: 29561296
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The safety of talimogene laherparepvec for the treatment of advanced melanoma.
    Gangi A; Zager JS
    Expert Opin Drug Saf; 2017 Feb; 16(2):265-269. PubMed ID: 27989216
    [TBL] [Abstract][Full Text] [Related]  

  • 4. (Neo)adjuvant systemic therapy for melanoma.
    van Zeijl MC; van den Eertwegh AJ; Haanen JB; Wouters MW
    Eur J Surg Oncol; 2017 Mar; 43(3):534-543. PubMed ID: 27453302
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Immunotherapy for malignant melanoma].
    Zaremba A; Zimmer L; Griewank KG; Ugurel S; Roesch A; Schadendorf D; Livingstone E
    Internist (Berl); 2020 Jul; 61(7):669-675. PubMed ID: 32462249
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A review of novel therapies for melanoma.
    Karimkhani C; Gonzalez R; Dellavalle RP
    Am J Clin Dermatol; 2014 Aug; 15(4):323-37. PubMed ID: 24928310
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Melanoma: An update on systemic therapies.
    Skudalski L; Waldman R; Kerr PE; Grant-Kels JM
    J Am Acad Dermatol; 2022 Mar; 86(3):515-524. PubMed ID: 34915056
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeted Therapy and Immunotherapy for Melanoma in Japan.
    Namikawa K; Yamazaki N
    Curr Treat Options Oncol; 2019 Jan; 20(1):7. PubMed ID: 30675668
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Kaposi's varicelliform eruption in a patient with metastatic melanoma and primary cutaneous anaplastic large cell lymphoma treated with talimogene laherparepvec and nivolumab.
    Miller DM; Trowbridge RM; Desai A; Drews RE
    J Immunother Cancer; 2018 Nov; 6(1):122. PubMed ID: 30454071
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment patterns of advanced malignant melanoma (stage III-IV) - A review of current standards in Europe.
    Harries M; Malvehy J; Lebbe C; Heron L; Amelio J; Szabo Z; Schadendorf D
    Eur J Cancer; 2016 Jun; 60():179-89. PubMed ID: 27118416
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combination Immunotherapy Development in Melanoma.
    Eggermont AMM; Crittenden M; Wargo J
    Am Soc Clin Oncol Educ Book; 2018 May; 38():197-207. PubMed ID: 30231333
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cutaneous head and neck melanoma in OPTiM, a randomized phase 3 trial of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor for the treatment of unresected stage IIIB/IIIC/IV melanoma.
    Andtbacka RH; Agarwala SS; Ollila DW; Hallmeyer S; Milhem M; Amatruda T; Nemunaitis JJ; Harrington KJ; Chen L; Shilkrut M; Ross M; Kaufman HL
    Head Neck; 2016 Dec; 38(12):1752-1758. PubMed ID: 27407058
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cutaneous Complications of Targeted Melanoma Therapy.
    de Golian E; Kwong BY; Swetter SM; Pugliese SB
    Curr Treat Options Oncol; 2016 Nov; 17(11):57. PubMed ID: 27645330
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An Overview of the Changing Landscape of Treatment for Advanced Melanoma.
    Lee CS; Thomas CM; Ng KE
    Pharmacotherapy; 2017 Mar; 37(3):319-333. PubMed ID: 28052356
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeted agents and immunotherapies: optimizing outcomes in melanoma.
    Luke JJ; Flaherty KT; Ribas A; Long GV
    Nat Rev Clin Oncol; 2017 Aug; 14(8):463-482. PubMed ID: 28374786
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetic drug evaluation of talimogene laherparepvec for the treatment of advanced melanoma.
    Burke EE; Zager JS
    Expert Opin Drug Metab Toxicol; 2018 Apr; 14(4):469-473. PubMed ID: 29557682
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Indirect Treatment Comparison of Talimogene Laherparepvec Compared with Ipilimumab and Vemurafenib for the Treatment of Patients with Metastatic Melanoma.
    Quinn C; Ma Q; Kudlac A; Palmer S; Barber B; Zhao Z
    Adv Ther; 2016 Apr; 33(4):643-57. PubMed ID: 26979173
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recent advances in malignant melanoma.
    Atkinson V
    Intern Med J; 2017 Oct; 47(10):1114-1121. PubMed ID: 28994264
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Talimogene laherparepvec (T-VEC) as cancer immunotherapy.
    Kohlhapp FJ; Zloza A; Kaufman HL
    Drugs Today (Barc); 2015 Sep; 51(9):549-58. PubMed ID: 26488034
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Melanoma update].
    Longvert C; Saiag P
    Rev Med Interne; 2019 Mar; 40(3):178-183. PubMed ID: 30527396
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.